Polymorphism of CYP2D6 and the influence to the drug metabolism

Abstract

Abstract: CYP2D6 is a member of cytochrome P450 gene family - a group of enzymes that is responsible for phase I metabolism and elimination of numerous endogenous substrates and a diverse array of drugs. It is now thought to be involved in the metabolism of up to 25% of the drugs that are in common use in the clinic, despite its low hepatic content (about 2 %). Among the drug-metabolizing cytochrome P450s, CYP2D6 is the only non-inducible enzyme and is highly polymorphic, which results in a large contribution of genetic variation to its inter-individual variation in enzyme activity and is an enzyme of great historical importance for pharmacogenetics. Here we summarize the polymorphism of CYP2D6 gene and their influence to drug metabolism.

Key words: CYP2D6, Genetic polymorphism, Drug metabolism , , , ,

CLC Number:

R969

HAN Lu, LIU Jie. Polymorphism of CYP2D6 and the influence to the drug metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 105-110.

References

[1] Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies:pharmacogenetic, pharmacoepigenetic and clinical aspects[J]. Pharmacol Ther, 2007, 116(3):496-526.
[2] Evans DA, Harmer D, Downham DY, et al.The genetic control of sparteine and debrisoquine metabolism in man withnew methods of analysing bimodal distributions[J]. J Med Genet, 1983, 20(5):321-329.
[3] Mahgoub A, Idle JR,Smith RL, et al. A population and familial study of defective alicyclic hydroxylation of debrisoquine among Egyptians[J]. Xenobiotica, 1979, 9(1):51-56.
[4] Yokota H, Takamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism[J]. Pharmacogenetics, 1993, 3(5):256-263.
[5] Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis[J]. J Pharmacol Exp Therapeut, 1995, 274(1):516-520.
[6] 李芹,王睿. 细胞色素P4502D6基因多态性和药物相互作用[J].中国临床药理学与治疗学, 2006,11(4):369-374.
[7] 华梓婷,郭养浩,孟春. 细胞色素P450的基因多态性与药物代谢[J]. 中国新药杂志, 2007,16 (7):510-515.
[8] Rendic S. Summary of information on human CYP enzymes:human P450 metabolism data[J]. Drug Metab Rev, 2002, 34(1/2):83-448.
[9] Boina N, Tramiak I, Medved V, et al. CYP2D6 genotype and psychotropic drug-induced adverse effects[J]. Period Boil, 2001, 103(1):309-314.
[10]Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers[J]. J Clin Psychopharmacol, 2007, 27(1):28-34.
[11]Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism[J]. New Engl J Med, 2004, 351(27):2827-2831.
[12]Daly AK, Brockmoller J, Broly F, et al.Nomenclature for human CYP2D6 alleles[J]. Pharmacogenetics,1996, 6(3):193-201.
[13]Zanger UM, Raimundo S, Eichelbaum M, et al.Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry[J]. Naunyn-Schmiedeberg's Arch Pharmacol,2004, 369 (1): 23-37.
[14]Ingelman-Sundberg M, Sim SC, Gomez A, et al.Influence of cytochrome P450 polymorphisms on drug therapies:Pharmacogenetic, pharmacoepigenetic and clinical aspects[J]. Pharmacol Ther, 2007, 116(3):496-526.
[15]Eichelbaum M, Ingelman-Sundberg M, Evans WE, et al.Pharmacogenomics and individualized drug therapy[J]. Annu Rev Med, 2006, 57:119-137.
[16]Bertilsson L, Dahl ML, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs[J]. Br J Clin Pharmacol, 2002, 53(2):111-122.
[17]Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea[J]. Mol Nutr Food Res, 2008, 52(7):755-763.
[18]Bozina N, Bradamante V, Lovri M. Genetic polymorphism of metabolic enzymes P450(CYP) as a susceptibility factor for drug response,toxicity,and cancer risk[J]. Arh Hig Rada Toksikol, 2009, 60(2):217-242
[19]Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects[J]. Clin Pharmacol Ther, 2002, 72(4):429-437.
[20]Lam YW, Gaedigk A, Ereshefsky L, et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6[J]. Pharmacotherapy, 2002, 22(8):1001-1006.
[21]Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetic of antidepressantsand antipsychotics: the contribution of allelic variations to the phenotype of drug response[J]. Mol Psychiatry, 2004, 9(5):442-473.
[22]Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers[J]. J Clin Psychopharmacol, 2007, 27(1):28-34.
[23]Stearns V, Johnson MD, Rae JM, et al.Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine[J]. J Natl Cancer Inst, 2003, 95(23):1758-1764.
[24]Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study[J]. Clin Pharmacol Ther, 2009, 85(1):31-35.